Certuity LLC Buys 28,752 Shares of Pfizer Inc. (NYSE:PFE)

Certuity LLC grew its stake in shares of Pfizer Inc. (NYSE:PFE) by 81.2% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 64,161 shares of the biopharmaceutical company’s stock after acquiring an additional 28,752 shares during the period. Certuity LLC’s holdings in Pfizer were worth $1,847,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Trifecta Capital Advisors LLC raised its stake in Pfizer by 3.7% in the third quarter. Trifecta Capital Advisors LLC now owns 9,197 shares of the biopharmaceutical company’s stock worth $305,000 after buying an additional 325 shares in the last quarter. Confluence Wealth Services Inc. raised its stake in Pfizer by 0.5% in the third quarter. Confluence Wealth Services Inc. now owns 65,053 shares of the biopharmaceutical company’s stock worth $2,158,000 after buying an additional 342 shares in the last quarter. Carr Financial Group Corp raised its stake in Pfizer by 3.3% in the third quarter. Carr Financial Group Corp now owns 11,012 shares of the biopharmaceutical company’s stock worth $344,000 after buying an additional 355 shares in the last quarter. Caldwell Sutter Capital Inc. grew its holdings in Pfizer by 0.5% in the third quarter. Caldwell Sutter Capital Inc. now owns 69,794 shares of the biopharmaceutical company’s stock worth $2,315,000 after purchasing an additional 364 shares during the last quarter. Finally, Bill Few Associates Inc. grew its holdings in Pfizer by 0.5% in the third quarter. Bill Few Associates Inc. now owns 80,820 shares of the biopharmaceutical company’s stock worth $2,681,000 after purchasing an additional 368 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

PFE has been the topic of several analyst reports. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Monday, April 15th. TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a report on Thursday, January 4th. Finally, Guggenheim initiated coverage on shares of Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target on the stock. Eleven equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $36.33.

Pfizer Price Performance

NYSE:PFE remained flat at $25.64 during mid-day trading on Tuesday. 21,109,945 shares of the company’s stock traded hands, compared to its average volume of 41,749,664. Pfizer Inc. has a one year low of $25.20 and a one year high of $40.37. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The company has a market capitalization of $145.19 billion, a PE ratio of 71.50, a price-to-earnings-growth ratio of 1.14 and a beta of 0.61. The business’s 50-day moving average price is $26.92 and its two-hundred day moving average price is $28.31.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. During the same period in the prior year, the company earned $1.14 earnings per share. The firm’s revenue was down 41.3% on a year-over-year basis. Analysts anticipate that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be issued a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 6.55%. The ex-dividend date is Thursday, May 9th. Pfizer’s payout ratio is 466.67%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.